提醒成功
搜索
| 产品规范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00025 |
| Application | Flow cytometry, animal model study |
| Aliases | epidermal growth factor receptor, EGF receptor |
| Size/Concentration | 1mg/5mg/20mg |
| Isotype | Human IgG1 kappa |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human EGFR / ErbB-1 |
| Formulation | PBS, pH 7.4 |
Description |
|---|
Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab. Like cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division. It has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 κ-chain. Nimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy. |
Nimotuzumab Biosimilar, EGFR Monoclonal Antibody B00025
规格:
- 1mg
- 5mg
- 20mg
数量:
-
+
说明书:
¥2275
-
咨询
-
收藏

微信/QQ登录


首页